Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.

image shows hand holding a nasal spray which administers the drug.

In the US, patients who start esketamine ($600 a dose) are asked about whether they have previously taken ketamine ($10 a dose), but not the other way round.

Associate Professor Rupert McShane, University of Oxford, says,

"History teaches us just how important it is to track patients who switch from one potentially addictive drug to another. European and UK regulators urgently need to ensure that treatments with ketamine, and other potentially addictive drugs, are all tracked in the same system along with esketamine. This same logic applies to people who are self-treating without a prescription. This sensible precaution would help prevent esketamine from suffering the same fate as benzodiazepines: overuse, backlash and stigma."

 

Patients' experiences matter – this sort of data platform will give them a voice.Associate Professor Rupert McShane.

 

Read the full article authored by Rupert McShane and Adam Winstock.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Helping People with Psychosis Feel Less Distressed May Help Reduce the Risk of Self-harm

New research shows that by lessening the severity and impact of persecutory symptoms of psychosis, it may be possible to reduce the likelihood of someone with psychosis having thoughts of suicide or harming themselves.

Ground-breaking Treatment Offers New Hope for Patients with Persecutory Delusions

Feeling Safe is a new treatment programme for persecutory delusions, which promises a step change in the treatment of severe mental health problems.

Depressive Symptoms and Risky Behaviours Among Adolescents in Low-and Middle-Income Countries

New meta-analysis, published in the Journal of the American Academy of Child & Adolescent Psychiatry, shows adolescents with depressive symptoms were more likely to engage in risky behaviours compared with non-depressed adolescents.

Adolescent Mental Health and Development in the Digital World

A new project has been awarded funding from the UKRI £24 million investment into improving the mental health and wellbeing of adolescents in the UK.

£24m Investment into Adolescent Mental Health to Enable Young People to Flourish

UKRI have announced a major £24 million investment into improving the mental health and wellbeing of adolescents in the UK. One of the projects being funded is led by Professor Kam Bhui in the Department of Psychiatry, it will bring together diverse creative-arts, digital and health experts to investigate how adverse childhood experiences (ACEs) can affect adolescents' mental health.

£36 Million Boost for AI Technologies to Revolutionise NHS Care

An Oxford project using artificial intelligence to develop digital triage tools for mental health clinicians (CHRONOS) is one of 38 projects supported by the second wave of the NHS AI Lab's AI in Health and Care Award.